Skip to main content
CGTX
NASDAQ Life Sciences

Cognition Q3 Loss Narrows to $4.1M; Cash Runs Into Q4 2027 as Nasdaq Deficiency Looms

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.683
Mkt Cap
$64.978M
52W Low
$0.55
52W High
$1.825
52W Position info
24% above low
Off High info
63% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

CGTX sits 24% above its 52-week low of $0.55.

Summary

Cognition Therapeutics posted a narrower $4.1M Q3 loss with $31.5M in cash and runway into Q4 2027, while disclosing a Nasdaq minimum-bid deficiency that must be cured by May 3, 2027.


Key Events · Earnings and Guidance · CGTX

  • Q3 Loss Narrows to $4.1M

    Net loss for the quarter ended September 30, 2026 was $4.145M, or $0.04 per share, versus $4.930M a year earlier. Nine-month loss fell to $12.647M from $20.144M.

  • Cash of $31.5M, Runway Into Q4 2027

    Cash, cash equivalents and restricted cash totaled $31.475M at September 30, 2026. Management says this funds operations into Q4 2027 assuming no usage from the 2025 ATM.

  • Nasdaq Minimum-Bid Deficiency

    Nasdaq notified the company on November 3, 2026 that its bid had been below $1.00 for 30 consecutive business days. It has until May 3, 2027 to close at $1.00 or higher for 10 straight days, with a reverse split the stated option.

  • ATM Leaves $68.0M of Headroom

    The company sold 5,550,659 shares under the 2025 ATM in the first nine months of 2026 for gross proceeds of about $7.0M; $68.0M remains available for future issuance.


Analysis · CGTX · Life Sciences

The quarter itself is an improvement: the net loss fell to $4.1M from $4.9M a year ago, and nine-month R&D dropped to $16.3M from $26.0M as trial activity slowed. With $31.5M of cash and equivalents, management says funding lasts into Q4 2027 without touching the $68.0M still available under the 2025 ATM — but that runway depends on continued NIA grant reimbursements and does not fund a Phase 3 program. Against that backdrop, the stock closed below $1.00 for 30 straight business days, and Nasdaq gave the company until May 3, 2027 to cure, with a reverse split the stated fallback. The clinical story is intact — FDA agreed in October on the DLB registrational design — but the balance sheet and the listing clock are now the binding constraints.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CGTX was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $65M. The 52-week trading range was $0.55 to $1.83. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CGTX - Latest Insights

CGTX
Nov 05, 2026, 6:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6833
Real-time Price: $0.5814 info
Change: -$0.1019 (-15%) info
Market Cap: $55.368M info
CGTX
Oct 22, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.800
Real-time Price: $0.5814 info
Change: -$0.2186 (-27%) info
Market Cap: $55.368M info
CGTX
Oct 22, 2026, 6:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7995
Real-time Price: $0.5814 info
Change: -$0.2181 (-27%) info
Market Cap: $55.368M info
CGTX
Oct 13, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.865
Real-time Price: $0.5814 info
Change: -$0.2836 (-33%) info
Market Cap: $55.368M info
CGTX
Aug 07, 2026, 7:30 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.13
Real-time Price: $0.5814 info
Change: -$0.5486 (-49%) info
Market Cap: $55.368M info